CTOs on the Move

Queens-Long Island Medical Group, P.C.

www.qlimg.com

 
Queens-Long Island Medical Group, P.C. is a Garden City, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.qlimg.com
  • 1000 Zeckendorf Blvd
    Garden City, NY USA 11530
  • Phone: 516.542.5500

Executives

Name Title Contact Details

Similar Companies

JJ WIld

JJ WIld is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayer Pharmaceutical Manufacturing Services

Bayer Pharmaceutical Manufacturing Services is a Shawnee, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Headspace Health

Headspace Health is a leading provider of mental health and wellbeing solutions, touching the lives of over 100 million people in 190 countries. Through our flagship Headspace brand, we provide mindfulness tools for everyday life, including meditations, sleepcasts, mindful movement, and focus exercises. Our enterprise brands, Headspace for Work and Ginger, are distributed through over 3,500 enterprises, including Starbucks, Adobe, Delta Air Lines, and Paramount; and through health plans such as Cigna. Our members and enterprise partners` employees have access to mindfulness and meditation tools, CBT, coaching, therapy, and psychiatry, ultimately helping them to be healthier and more productive.

Croes Communications

Croes Communications, Inc is a Oak Hall, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.